Ann Fudge - Novartis Non-Executive Independent Director

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;padding-top: 25px;;'>NO</div>
NVS -- USA Stock  

Fiscal Quarter End: 30th of June 2020  

  Director
Ms. Ann Marie Fudge was NonExecutive Independent Director at Novartis Inc. since February 26, 2008. She is Member of the Compensation Committee the Governance, Nomination and Corporationrationrate Responsibilities Committee and the Risk Committee. Ms. Fudge is chair of the United States Program Advisory Panel of the Bill Melinda Gates Foundation, and vice chairman of Bostonbased WGBH Public Media. She is also a nonexecutive director of Northrop Grumman Corporationrationration in the US, and a member of the visiting committee of Harvard Business School in the US. She served as a nonexecutive director of Unilever, London and Rotterdam, from 2009 to 2018, and as vice chairman and senior independent director of Unilever from 2015 to 2018. Additionally, she was a board member of General Electric Co. in the US from 1999 to 2015
Age: 68  Director Since 2008  MBA    
41 61 324 1111  http://www.novartis.com
Fudge received her bachelor?s degree from Simmons College and her MBA from Harvard Business School. She is former chairman and CEO of Young & Rubicam Brands, New York. Before that, she served as president of the Beverages, Desserts and Post Division of Kraft Foods Inc.

Novartis Management Efficiency

Novartis AG has Return on Asset of 0.0821 % which means that on every $100 spent on asset it made $0.0821 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.1782 % implying that it generated $0.1782 on every 100 dollars invested. Novartis management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. Novartis Return on Average Equity is relatively stable at the moment as compared to the last year. Novartis reported last year Return on Average Equity of 0.17. As of 06/04/2020, Return on Invested Capital is likely to grow to 0.26, while Return on Average Assets are likely to drop 0.08. Novartis Total Assets are relatively stable at the moment as compared to the last year. Novartis reported last year Total Assets of 118.37 Billion. As of 06/04/2020, Assets Non Current is likely to grow to about 102 B, while Asset Turnover is likely to drop 0.37. Novartis Total Liabilities is relatively stable at the moment as compared to the last year. Novartis reported last year Total Liabilities of 62.82 Billion. As of 06/04/2020, Liabilities Non Current is likely to grow to about 35.6 B, while Current Liabilities is likely to drop slightly above 23.7 B.
The company has 29.33 B in debt with debt to equity (D/E) ratio of 52.8 . This implies that the company may be unable to create cash to meet all of its financial commitments. Novartis AG has Current Ratio of 1.02 demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Per WoldOlsenGilead Sciences
2010
William HarrisonMerck Company
2009
Stacey CartwrightGlaxoSmithKline PLC
2011
Philip HamptonGlaxoSmithKline PLC
2015
Antonio ParesGrifols S A
2014
Inigo MardonesGrifols S A
2017
William PerezJohnson Johnson
2007
Ronald WilliamsJohnson Johnson
2011
Thomas CechMerck Company
2009
Craig ThompsonMerck Company
2008
Urs RohnerGlaxoSmithKline PLC
2015
Cabot BrownGW Pharmaceuticals Plc
2013
Roy AndersonGlaxoSmithKline PLC
2007
Genevieve BergerAstrazeneca PLC
2012
William KaelinEli Lilly And
2012
Robert BertoliniBristol Myers Squibb
2017
William WaldegraveGW Pharmaceuticals Plc
2017
Steven MayerGrifols S A
2016
Manvinder BangaGlaxoSmithKline PLC
2016
Philip BroadleyAstrazeneca PLC
2017
Stephanie BurnsGlaxoSmithKline PLC
2007

Company Summary

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company was founded in 1895 and is headquartered in Basel, Switzerland. Novartis operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 109000 people.Novartis AG (NVS) is traded on BATS Exchange in USA. It is located in Lichtstrasse 35 and employs 109,000 people. Novartis AG was previously known as NOVARTIS AG and was traded on BATS Exchange under the symbol NVSEF. Novartis is listed under Pharmaceutical Products category by Fama And French industry classification.

Novartis AG Leadership Team

Ton Buechner, Non-Executive Independent Director
Verena Briner, Non-Executive Independent Member of the Board
Chris Ilsley, President CEO
Steven Baert, Chief People & Organization Officer, Member of the Executive Committee
Richard Saynor, Chief Executive Officer of Sandoz, Member of the Executive Committee
Richard Francis, Member of the Executive Committee and Division Head, Sandoz
Daniel Vasella, Honorary Chairman of the Board
Pierre Landolt, Member of the Board of Directors
Elizabeth Doherty, Non-Executive Independent Director
Erwin Vanhaecke, Head Novartis Group Quality
Elizabeth Barrett, CEO, Novartis Oncology
Mark Fishman, Member of the Executive Committee and President of Novartis Institute for BioMedical Research (NIBR)
Charlotte PamerWieser, Corporate Secretary
Shannon Klinger, Chief Risk and Compliance Officer, Group General Counsel
Samir Shah, Global Head Investor Relations
David Epstein, Member of the Executive Committee, Division Head, Pharmaceuticals
Srikant Datar, Non-Executive Independent Director
MarieFrance Tschudin, President of Novartis Pharmaceuticals, Member of the Executive Committee
Simon Moroney, Director
Francesco Balestrieri, Chief Executive Officer of Sandoz, Member of the Executive Committee
Steffen Lang, Global Head of Novartis Technical Operations, Member of the Executive Committee
Joerg Reinhardt, Independent Non-Executive Chairman of the Board
Paul Hudson, Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive Committee
Brian McNamara, Member of the Management Board, Division Head, Novartis OTC
Andrews C, Non-Executive Independent Director
Michele Galen, Head Communications
Charles Sawyers, Non-Executive Independent Member of the Board
John Tsai, Head of Global Drug Development and Chief Medical Office, Member of the Executive Committee
Dimitri Azar, Non-Executive Independent Director
Frans Houten, Non-Executive Independent Director
Nancy Andrews, Non-Executive Independent Director
Susanne Schaffert, CEO Novartis Oncology, Member of the Executive Committee
Enrico Vanni, Independent Non-Executive Vice Chairman of the Board
Bertrand Bodson, Chief Digital Officer, Member of the Executive Committee
Robert Weltevreden, Head of Novartis Business Services (NBS), Member of the Executive Committee
Andre Wyss, Member of the Executive Committee, Novartis Business Services and Country President for Switzerland
Bruno Strigini, CEO of Novartis Oncology, Member of the Executive Committee
Vasant Narasimhan, Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee
Alex Krauer, Honorary Chairman of the Board
Michael Ball, CEO of Alcon, Member of the Executive Committee
Jeffrey George, Member of the Executive Committee and Division Head, Sandoz
Patrice Bula, Non-Executive Independent Director
Peter Kornicker, Chief Compliance Officer
Andreas Planta, Non-Executive Independent Director
Joseph Jimenez, CEO, Member of the Executive Committee
Ulrich Lehner, Vice Chairman of the Board of Directors, Non-Executive Director
William Winters, Non-Executive Independent Member of the Board
Ann Fudge, Non-Executive Independent Director
George Gunn, Member of the Executive Committee, Division Head, Novartis Animal Health of Head, Corporate Responsibility
Paul Arkel, Head of Corporate Strategy and External Affairs
James Bradner, President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee
Klaus Moosmayer, Chief Ethics, Risk and Compliance Officer, Member of the Executive Committee
Felix Ehrat, General Counsel and General Counsel of Novartis International Ag
Harry Kirsch, Chief Financial Officer, Member of the Executive Committee
Andrin Oswald, Member of the Executive Committee, Division Head, Vaccines and Diagnostics
Bridgette Heller, Director

Stock Performance Indicators

Current Sentiment - NVS

Novartis AG Investor Sentiment

Predominant part of Macroaxis users are now bullish on Novartis AG. What is your trading attitude regarding investing in Novartis AG? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Please also try Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page